Plain English Summary
Background and study aims
Periodontitis is a chronic inflammatory disease affecting the tissue surrounding the teeth, and if left untreated it may result in bone damage and subsequent tooth loss. The disease is very common worldwide, in Sweden affecting approximately 1/3 of the population. Rheumatoid arthritis (RA) is a lifelong autoimmune disease, where the normally protective immune system attacks the joints, resulting in swelling, stiffness and pain. This incurable disease affects approximately 1% of the world’s population, mostly women. Previous studies have shown that patients with RA may have increased risk of periodontitis in general and that non-surgical periodontal treatment may have beneficial effects on RA disease activity. The aim of this study is to investigate the severity of periodontitis in patients with RA and weather frequent periodontal treatment (every three months) results in improvement of RA disease activity and periodontal parameters in patients with RA and periodontitis.
Who can participate?
Patients with RA and periodontal disease, ≥ 18 .
What does the study involve?
Participants receive a dental examination at the beginning of the study. Those with periodontitis will be randomly divided to one of two groups. Those in the first groupeceive a more frequent periodontal treatment every three months, and those in the second group receive periodontal treatment only at the first visit. The periodontal treatment includes oral hygiene instructions and removal of plaque and tartar by a dental professional. Patients with severe periodontitis in need of specialist treatment are referred to and treated by a dentist who specializes in periodontal disease/a periodontist.
What are the possible benefits and risks of participating?
The main benefits of participating in the study include surveillance and treatment of the periodontal disease performed frequently (every three months) by a dentist. Also the patients in the control group benefit from conventional periodontal treatment at the inclusion into the study. The side effects of periodontal treatment include sore gums and gum recession due to reduced inflammation. This is a low risk study since all the participants receive conventional periodontal treatment during the first visit as well as surveillance of the periodontitis throughout the course of the study.
Where is the study run from?
Karolinska University Hospital (Sweden)
When is study starting and how long is it expected to run for?
December 2015 to December 2018.
Who is funding the study?
Partly funded by the Stockholm County Council, the collaborative European Union's FP7 Research Project TRIGGER, Karolinska Institutet, the Swedish Research Council, the Swedish Dental Society and others.
Who is the main contact?
1. Associate Professor Tülay Yucel-Lindberg
Tulay.Lindberg@ki.se
2. PhD, DDS, Kaja Eriksson
kaja.eriksson@ki.se
Trial website
Contact information
Type
Scientific
Primary contact
Dr Tülay Yucel-Lindberg
ORCID ID
http://orcid.org/0000-0003-0129-8809
Contact details
Department of Dental Medicine
Division of periodontology
Karolinska Institutet
Stockholm
141 04
Sweden
Additional identifiers
EudraCT number
ClinicalTrials.gov number
Protocol/serial number
2009/792-31/4
Study information
Scientific title
The severity of periodontitis and the effects of periodontal treatment on disease activity of patients with rheumatoid arthritis as well as the influence of medication on periodontitis: A randomized controlled trial
Acronym
Periodontitis in RA (PEIRA)
Study hypothesis
The hypotheses of this study are:
1. Severe form of periodontitis is more common in seropositive (ACPA/RF) patients with RA as compared to seronegative.
2. Frequent periodontal treatment reduces rheumatoid arthritis disease activity, and related autoimmune and inflammatory parameters.
3. The microbial profile differs based on rheumatological and/or periodontal characteristics in patients with RA.
Ethics approval
1. Regional Ethical Review Board Stockholmm, 10/06/2009, ref: Dnr 2009/792-31/4
2. Regional Ethical Review Board Stockholmm, 30/04/2015, ref: 2015/766-32
Study design
Prospective randomized interventional clinical controlled trial
Primary study design
Interventional
Secondary study design
Trial setting
Hospitals
Trial type
Treatment
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Condition
Periodontitis and Rheumatoid Arthritis
Intervention
After a full-mouth dental and periodontal examination, participants with periodontitis are randomized to one of two groups.
Those in the first group receive conventional periodontal treatment only at the time of inclusion into the study (control group).
Those in the second group undergo the periodontal treatment every three months (intervention group) for one year year. The conventional periodontal treatment includes oral hygiene instructions, supra- and subgingival scaling and root planning. Patients in need of specialist treatment (e.g. surgical periodontal treatment) are remitted to periodontal clinic.
Participants are assessed for their rheumatoid arthritis activity at baseline and at the study end. Participants are also evaluated for their periodontal parameters such as probing pocket depth, clinical attachment loss, antibodies, microbial profiles and inflammatory mediators.
Intervention type
Other
Phase
Drug names
Primary outcome measures
1. Rheumatoid arthritis (RA) disease activity is measured using the DAS28 score, HAQ score at baseline and one year
2. Periodontal parameters (such as probing pocket depth, clinical attachment loss) are measured using the methods of measurement of periodontal disease/parameters at baseline and months three, six, nine, and twelve
Secondary outcome measures
1. The microbial profile is assessed using sequencing technology throughout the study (the specific time points depend on the availability of the resources as well as the instruments at core facility)
2. Antibody levels (such as ACPA/RF, periodontal pathogens etc) are measured using multiplex immunoassay, nephelometry and/or ELISA technique at baseline and one year
3. Levels of inflammatory mediators are measured using Luminex immunoassay at baseline and one year
Overall trial start date
01/05/2009
Overall trial end date
31/12/2018
Reason abandoned
Eligibility
Participant inclusion criteria
1. ≥ 18 years of age
2. Fulfilling the 2010 ACR criteria for RA
3. Moderate to severe periodontitis, defined according to the classification criteria of the CDC Working Group meant for usage in Population-Based Surveillance of Periodontitis
4. Written informed consent to participate
5. Swedish national registration number
Participant type
Patient
Age group
Adult
Gender
Both
Target number of participants
100
Participant exclusion criteria
1. Antibiotic treatment ≤3 months prior to inclusion into the study
2. Periodontal treatment (surgical or non-surgical) ≤3 months prior to inclusion into the study
3. Pregnancy
4. Simultaneous participation in other interventional studies
Recruitment start date
01/12/2015
Recruitment end date
31/12/2017
Locations
Countries of recruitment
Sweden
Trial participating centre
Rheumatology Clinics at Karolinska University Hospital (Huddinge and Solna)
141 86 Stockholm (Huddinge)
171 76 Stockholm (Solna)
Stockholm
141 86
Sweden
Funders
Funder type
Not defined
Funder name
Stockholms Läns Landsting
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
Vetenskapsrådet
Alternative name(s)
Swedish Research Council, VR
Funding Body Type
government organisation
Funding Body Subtype
government non-federal
Location
Sweden
Funder name
Swedish Dental Society
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
Swedish Rheumatic Foundation
Alternative name(s)
Funding Body Type
Funding Body Subtype
Location
Funder name
Karolinska Institutet
Alternative name(s)
Karolinska Institute, KI
Funding Body Type
government organisation
Funding Body Subtype
government non-federal
Location
Sweden
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer reviewed journal with intent to publish 2019/2020
IPD sharing statement:
The data sharing plans for the current study are unknown and will be made available at a later date
Intention to publish date
01/01/2020
Participant level data
To be made available at a later date
Results - basic reporting
Publication summary